Compass Therapeutics (CMPX) Profit After Tax (2018 - 2026)

Compass Therapeutics has reported Profit After Tax for 9 years, with the latest figure at -$18.3 million in Q1 2026.

• Quarterly Profit After Tax fell 10.12% year-over-year to -$18.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$68.1 million (down 23.61% YoY) and the FY2025 annual result came in at -$66.4 million, down 34.52% from the prior year.
• Profit After Tax slipped to -$18.3 million in Q1 2026 per CMPX's latest filing, from -$15.7 million in the prior quarter.
• Over five years, Profit After Tax peaked at -$7.2 million in Q1 2022 and troughed at -$19.9 million in Q2 2025.
• A 5-year average of -$12.7 million and a median of -$12.1 million in 2022 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2022 and 2023: Profit After Tax sank 102.58% in 2022, then advanced 18.32% in 2023.
• Over 5 years, Profit After Tax stood at -$11.6 million in 2022, then declined by 12.78% to -$13.1 million in 2023, then slipped by 18.4% to -$15.5 million in 2024, then retreated by 1.47% to -$15.7 million in 2025, then dropped by 16.59% to -$18.3 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$18.3 million, -$15.7 million, and -$14.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.